GlassScriptPhysician profile
Michael J Schutz
NPI 1104872167
$2,573.02
in general payments reported to CMS, 2019-2025
37 companies · $539 in 2025
The $539 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $514 · 2020: $43.06 · 2021: $153 · 2022: $596 · 2023: $339 · 2024: $389 · 2025: $539.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,267.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,266.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $186.52 | 2022-2025 | Enhertu, Calquence |
| Boston Scientific Corporation | $181.08 | 2019 | |
| Palette Life Sciences, INC. | $179.48 | 2022 | |
| Astellas Pharma US INC | $151.95 | 2022-2025 | Xtandi, Padcev |
| Daiichi Sankyo INC. | $151.10 | 2022-2025 | Enhertu, Injectafer |
| Medtronic USA, INC. | $142.35 | 2019 | |
| Pfizer INC. | $140.68 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $137.76 | 2022-2025 | |
| Incyte Corporation | $133.59 | 2021-2025 | Jakafi, Zynyz, Monjuvi |
| Merck Sharp & Dohme LLC | $103.06 | 2022-2024 | Keytruda, Lynparza |
| Amgen INC. | $101.19 | 2020-2022 | |
| Comsort, INC | $100.00 | 2019 | |
| Abbvie INC. | $98.68 | 2021-2024 | |
| Lilly USA, LLC | $64.51 | 2022-2023 | Verzenio, Jaypirca, Retevmo |
| Seagen INC. | $57.49 | 2022-2023 | Tukysa, Adcetris |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novocure INC. | $56.32 | 2024 | Optune |
| Morphosys, US INC. | $46.89 | 2022-2023 | Monjuvi |
| Sumitomo Pharma America, INC. | $46.78 | 2024-2025 | Orgovyx |
| Janssen Biotech, INC. | $44.88 | 2022-2025 | Tecvayli |
| Medtronic, INC. | $41.48 | 2021 | |
| Geron Corporation | $34.09 | 2025 | Rytelo |
| Stemline Therapeutics INC. | $32.99 | 2024 | Orserdu |
| Teleflex LLC | $30.00 | 2021 | |
| Genmab U.S., INC. | $28.94 | 2022-2023 | Tivdak |
| Eisai INC. | $28.67 | 2022 | |
| Emd Serono, INC. | $27.76 | 2021-2022 | |
| Bioprotect Medical, INC. | $27.74 | 2025 | Bioprotect Balloon Implant System |
| Adaptive Biotechnologies Corporation | $24.80 | 2024 | Clonoseq |
| Takeda Pharmaceuticals U.S.A., INC. | $23.35 | 2022 | |
| Puma Biotechnology, INC. | $22.80 | 2025 | |
| Immunitybio, INC. | $21.06 | 2025 | |
| Jazz Pharmaceuticals INC. | $18.94 | 2024 | |
| Genentech USA, INC. | $18.75 | 2025 | Polivy |
| Solventum Corporation | $18.68 | 2025 | Activ.A.C. |
| Novartis Pharmaceuticals Corporation | $18.38 | 2025 | |
| Dendreon Pharmaceuticals LLC | $16.18 | 2025 | Provenge |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.10 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Schutz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.